Chimeric antigen receptor‐modified ( CAR )‐T cells have demonstrated impressive results in
the treatment of haematological malignancies. However, cytokine release syndrome ( CRS …

We previously reported durable responses in relapsed or refractory (R/R) chronic
lymphocytic leukemia (CLL) patients treated with CD19-targeted chimeric antigen receptor-engineered …

Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric antigen
receptor–modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in …

Lymphodepletion chemotherapy followed by infusion of CD19-specific chimeric antigen
receptor–modified (CAR) T cells has produced impressive antitumor responses in patients with …

Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor–modified
T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had …

A subset of patients with severe COVID-19 develop profound inflammation and multi-organ
dysfunction consistent with a “Cytokine Storm Syndrome” (CSS). In this review we compare …

Coronavirus disease 2019 (COVID-19) severity appears to parallel the host immune response,
with a subset of patients developing COVID-19 cytokine storm syndrome (CSS). 1 Serum …

Lymphodepletion chemotherapy with CD19-targeted chimeric antigen receptor–modified T (CAR-T)-cell
immunotherapy is a novel treatment for refractory or relapsed B-cell …

Autologous T cells engineered to express a CD19-specific chimeric antigen receptor (CAR)
have produced impressive minimal residual disease–negative (MRD-negative) complete …

Factors associated with durable remission after CD19 chimeric antigen receptor (CAR)-modified
T-cell immunotherapy for aggressive B-cell non-Hodgkin lymphoma (NHL) have not …